Back to results
US 2026/0049291 A1Published application
Chimeric poxviruses
AssigneeTransgene S.A.
InventorsPhilippe ERBS, Annie FINDELI
Life of this patent
Estimating the term…
Abstract
The present invention relates to a chimeric poxvirus with improved anticancer activity (higher cancer cell killing capacities and better tumor selectivity), as well as variant version thereof with one or more altered viral genes, recombinant versions thereof comprise one or more nucleic acid(s) of interest and recombinant variant versions thereof, all of which may be included in a composition and used for the treatment of a disease, in particular proliferative disease, notably cancers.
Claims29
-55. (canceled)
A chimeric poxvirus comprising a nucleic acid sequence having a sequence identity of at least 96.6% with SEQ ID NO:1.
Dependencies are inferred from the claim text.